Pharvaris N.V. ($PHVS) Investment Thesis: A Compelling Buy Opportunity in...
Pharvaris N.V. presents a promising investment opportunity in the biotech sector, with a Buy recommendation and a 12-month price target of $38.00. At the heart of this is deucrictibant, an...